13th Workshop
Eurordis Round Table of Companies

"Patients'Access to OMPs, Innovative Pricing Schemes and National Measures in a Global Financial & Economic Crisis Environment"

13th December 2010

Les Salons de l'Aéro-Club de France
6, rue Galilée – 75116 Paris

Agenda

8:30 Welcome & coffee

MORNING: 9:00 - 12:45
Chairpersons:
Giulia Del Brenna (DG Enterprise, European Commission)
François Meyer (HAS – EUnetHTA)

9:00 – 9:10: *Welcome address*

9:10 – 9:40: "Comparative Pricing of the Most Common Orphan Drugs across Europe"**, Steven Flostrand (Creativ-Ceutical, Luxembourg) 10'question time**

9:40 – 10:10: "Rare Disease National Alliances and the Issue of Patients' Access to Orphan Drugs", **Fabrizia Bignami (EURORDIS)**; **presented by Yann Le Cam (CEO of EURORDIS) 10' question time**

10:10 – 10:55: "Industry Representatives on their Recent Experiences regarding Pricing and Reimbursement at the National Level", **Andras Fehervary (Novartis, Italy), Katia Finck (Shire HGT, France), Zéra Tellier (LFB Biomédicaments, France) 10' question time**

10:55 – 11:25 COFFEE BREAK

11:25 – 11:55: "New Approaches for Drug Pricing", **John Hutton (University of York, UK) 10' question time**

11:55 – 12:50: "What are Pharmaceutical Companies and National Competent Authorities ready to do or accept to Reach a Common Agreement? What are the Limits of their Respective Efforts?" **Panel discussion:** speakers and panel members **(Ri de Ridder – INAMI, Belgium)**

LUNCH:

12:50 – 14:00

AFTERNOON: 14:00 -17:00
Chairperson:
Yann Le Cam (EURORDIS)

14:00 – 14:15: **Introduction to the parallel breakout sessions and presentation of the 4 discussion topics**, Maria Mavris, EURORDIS

14:15 - 15:30: Parallel Breakout Sessions

Topics/groups:

1. Considering the first innovative approaches and concrete experiences, what new pricing scheme could be implemented for orphan drugs in the upcoming years? (e.g. secured sale volumes, risk sharing, …)

Rapporteurs: Andrea Rappagliosi (GSK, Belgium), Bengt Jönsson (Stockholm School of Economics, Sweden).

2. Which coordinated mechanism of access to orphan drugs is needed at the European level?

Rapporteurs: Giulia Del Brenna (EC-DG Enterprise, Belgium), Lugdivine Le Dez (Alexion, Belgium).

3. Some price containment measures are put in place in some Member States, how to handle the specific case of Orphan Drugs?

Rapporteurs: Elke Hunsche (Actelion, Switzerland), Dorica Dan (Romanian Rare Disease National Alliance).

4. What best practices should be implemented at national level to ensure that stakeholders have a real interaction and participation in the different aspects related to patients' access to orphan drug?

Rapporteurs: Jean Mossman (HTAi Patient/Citizen Interest Group, UK), Raquel Luengo (Madrid HTA Agency, Spain).

15:30 – 16:15: Feedback from the parallel groups presented by the 4 rapporteurs

16:15 – 17:00: Discussion

17:00 **End of Workshop**